<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017325</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN1001 PCM301-FU5</org_study_id>
    <nct_id>NCT04017325</nct_id>
  </id_info>
  <brief_title>European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up</brief_title>
  <official_title>A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Post Study 5-year Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steba Biotech S.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Drug Development Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steba Biotech S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open observational extended follow-up study of patients originally randomized into
      TOOKAD® Soluble VTP therapy or active surveillance (control group). Additional 60-month
      follow-up study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open observational extended follow-up study of patients originally randomized into
      TOOKAD® Soluble VTP therapy or active surveillance (control group). No intervention or
      further intervention with TOOKAD® Soluble is mandated in this additional 60-month follow-up
      study where patients in the original TOOKAD® Soluble group and active surveillance (control)
      group are both managed by their physician as appropriate to their condition using any
      treatment available following a 'local standard of care' principle from the end of the trial
      (M24) up to the end of follow-up (M84). Management decisions are entirely left to clinicians
      and their patients in this pragmatic extension of the trial (no criteria imposed) where
      standard of care that reflects clinical practice within each centre is applied.

      All patients originally randomised in study CLIN1001 PCM301, whether allocated to the TOOKAD®
      Soluble VTP arm (n=206) or Active surveillance arm (n=207 and who did not withdraw their
      consent will be included in this extension study.

      This extension study consists of 2 different follow-up:

        -  a follow-up of patients via investigators

        -  and a follow-up via interviews directly with patients
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 17, 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>Progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer in men initially randomized to TOOKAD® Soluble VTP compared to men originally randomized on active surveillance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Other prostate cancer therapy</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>Use of other prostate cancer therapy: radical therapy (surgery, radiotherapy, cryotherapy, ultrasound therapy), hormonal therapy or chemotherapy or any therapy indicated for the treatment of prostate cancer in the countries of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate cancer-related death.</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>Any death related to Prostate cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of cancer</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>The proportion of absence of cancer at biopsy (when available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radical therapy</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>The rate of prostate cancer radical therapy;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer burden</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>The total cancer burden in the prostate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary incontinence</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>The description of incontinence in terms of mean, median, SD, inter-quartile ranges, min-max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile dysfunction</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>The description of erectile dysfunction in terms of mean, median, SD, inter-quartile ranges, min-max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urethral stenosis</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>The rate of urethral stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer complication</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Questionnaires Quality of life</measure>
    <time_frame>Over the 5 years of follow up</time_frame>
    <description>Overal Quality of Life will be recorded for potential utility and descriptives studies</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">374</enrollment>
  <condition>Cancer of the Prostate</condition>
  <arm_group>
    <arm_group_label>TOOKAD VTP TREATMENT</arm_group_label>
    <description>Subjects randomized in the treatment arm (TOOKAD VTP treatment) in the initial period of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active surveillance</arm_group_label>
    <description>Subjects randomized in the control group (active surveillance) in the initial period of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention (post study follow up)</intervention_name>
    <description>No intervention (post study follow up)</description>
    <arm_group_label>Active surveillance</arm_group_label>
    <arm_group_label>TOOKAD VTP TREATMENT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with localized low risk prostate cancer initialy randomized in the study CLIN 1001
        PCM301
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects originally randomized in study CLIN1001 PCM301 are included in this
             follow-up study. As a reminder, they all met the following criteria at entry (from the
             original protocol):

               1. Low risk prostate cancer diagnosed using one trans-rectal ultrasound guided
                  biopsy (TRUS) using from 10 to 24 cores, within 12 months of enrolment and
                  showing the following:

                    -  Gleason 3 + 3 prostate adenocarcinoma as a maximum,

                    -  Two (2) to three (3) cores positive for cancer. Patients with only one
                       positive core can be included provided they have at least 3 mm of cancer
                       core length.

                    -  A maximum cancer core length of 5 mm in any core.

               2. Cancer clinical stage up to T2a (pathological or radiological up to T2c disease
                  permitted).

               3. Serum prostate specific antigen (PSA) of 10 ng/mL or less.

               4. Prostate volume equal or greater than 25 cc and less than 70 cc.

               5. Male subjects aged 18 years or older.

        Exclusion Criteria:

          -  As a reminder, all subjects originally randomized did not met the following criteria
             at entry (from the original protocol):

               1. Unwillingness to accept randomization to either of the two arms of the study.

               2. Any prior or current treatment for prostate cancer, including surgery, radiation
                  therapy (external or brachytherapy) or chemotherapy.

               3. Any surgical intervention for benign prostatic hypertrophy.

               4. Life expectancy less than 10 years.

               5. Any condition or history of illness or surgery that may pose an additional risk
                  to men undergoing the VTP procedure.

               6. Participation in another clinical study or recipient of an investigational
                  product within 1 month of study entry.

               7. Subject unable to understand the patient's information document, to give consent
                  or complete the study tasks. Subject in custody and or in residence in a nursing
                  home or rehabilitation facility.

               8. Contra-indication to MRI (e.g., pacemaker, history of allergic reaction to
                  gadolinium), or factors excluding accurate reading of pelvic MRI (e.g., hip
                  prosthesis).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mark EMBERTON, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College of London Hospital , United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology-Tampere University Hospital-</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU)</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Médipole</name>
      <address>
        <city>Cabestany</city>
        <zip>66330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Sévigné</name>
      <address>
        <city>Cesson Sévigné</city>
        <zip>35512</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris (IMM)</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35 033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Urologique Nantes</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Krankenahaus GmbH</name>
      <address>
        <city>Bergisch Gladbach</city>
        <zip>51465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATURO-Gemeinschaftspraxis für Urologie und Andrologie</name>
      <address>
        <city>Berlin-Wilmersdorf</city>
        <zip>D-14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot; der Technischen Universität</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Emmendingen</city>
        <zip>79132</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinzenz Krankenhaus - Department of Urology</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität München</name>
      <address>
        <city>Munich</city>
        <zip>D - 81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie 24</name>
      <address>
        <city>Nuremberg</city>
        <zip>90491</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology-Hospital Clinic, University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Del Rocio-Department Urology</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Urology-University Hospital-</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital (KCH)</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital (UCLH)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford John Radcliffe Hospital Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

